DK3962601T3 - 5-HT2A-agonister til anvendelse til behandling af depression - Google Patents
5-HT2A-agonister til anvendelse til behandling af depression Download PDFInfo
- Publication number
- DK3962601T3 DK3962601T3 DK20808308.9T DK20808308T DK3962601T3 DK 3962601 T3 DK3962601 T3 DK 3962601T3 DK 20808308 T DK20808308 T DK 20808308T DK 3962601 T3 DK3962601 T3 DK 3962601T3
- Authority
- DK
- Denmark
- Prior art keywords
- depression
- treatment
- ht2a agonists
- ht2a
- agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207578 | 2019-11-07 | ||
| US17/090,457 US11246860B2 (en) | 2019-11-07 | 2020-11-05 | 5-HT2A agonists for use in treatment of depression |
| PCT/EP2020/081357 WO2021089824A1 (en) | 2019-11-07 | 2020-11-06 | 5-ht2a agonists for use in treatment of depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3962601T3 true DK3962601T3 (da) | 2023-09-04 |
Family
ID=68502828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20808308.9T DK3962601T3 (da) | 2019-11-07 | 2020-11-06 | 5-HT2A-agonister til anvendelse til behandling af depression |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11246860B2 (da) |
| EP (1) | EP3962601B1 (da) |
| JP (1) | JP7566021B2 (da) |
| CN (1) | CN114761083B (da) |
| AU (1) | AU2020379225B2 (da) |
| BR (1) | BR112022008037A2 (da) |
| CA (1) | CA3156513A1 (da) |
| DK (1) | DK3962601T3 (da) |
| ES (1) | ES2953926T3 (da) |
| FI (1) | FI3962601T3 (da) |
| HR (1) | HRP20230856T1 (da) |
| HU (1) | HUE062369T2 (da) |
| IL (1) | IL292585B2 (da) |
| LT (1) | LT3962601T (da) |
| MA (1) | MA55821B1 (da) |
| MD (1) | MD3962601T2 (da) |
| PL (1) | PL3962601T3 (da) |
| PT (1) | PT3962601T (da) |
| SI (1) | SI3962601T1 (da) |
| WO (1) | WO2021089824A1 (da) |
| ZA (1) | ZA202204809B (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246860B2 (en) * | 2019-11-07 | 2022-02-15 | Lophora ApS | 5-HT2A agonists for use in treatment of depression |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| KR20260044248A (ko) | 2020-08-18 | 2026-04-01 | 사이빈 아이알엘 리미티드 | 치료 펜에틸아민 조성물 및 사용 방법 |
| JP2024516827A (ja) | 2021-04-30 | 2024-04-17 | マインド メディシン， インコーポレイテッド | Ｌｓｄ塩結晶形態 |
| WO2022234010A1 (en) * | 2021-05-06 | 2022-11-10 | Lophora ApS | Acid addition salts of (s)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and (s)-3-(2-methoxy-5-(methylthio)-4-(trifluoromethyl)phenyl)piperidine, specific polymorphs thereof and methods for their manufacture |
| IL309842A (en) * | 2021-07-26 | 2024-02-01 | Univ Louisiana State | Compounds and methods for treating situations where the response depends on 5-HT2 |
| AU2022331315B2 (en) | 2021-08-19 | 2025-10-16 | Definium Therapeutics US, Inc. | Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications |
| WO2024181024A1 (ja) * | 2023-03-02 | 2024-09-06 | 本田技研工業株式会社 | 組成物 |
| WO2025008804A1 (en) * | 2023-07-06 | 2025-01-09 | M – Path Biopharma Ltd. | Combination therapy for amelioration of side effects of estrogen receptor inhibitor treatment |
| WO2026073180A2 (en) * | 2024-09-30 | 2026-04-02 | Revolution Medicines, Inc. | Synthesis of ras inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6608101B1 (en) | 2000-06-20 | 2003-08-19 | Atherogenics, Inc. | 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| US11246860B2 (en) * | 2019-11-07 | 2022-02-15 | Lophora ApS | 5-HT2A agonists for use in treatment of depression |
-
2020
- 2020-11-05 US US17/090,457 patent/US11246860B2/en active Active
- 2020-11-06 IL IL292585A patent/IL292585B2/en unknown
- 2020-11-06 MD MDE20220277T patent/MD3962601T2/ro unknown
- 2020-11-06 EP EP20808308.9A patent/EP3962601B1/en active Active
- 2020-11-06 SI SI202030239T patent/SI3962601T1/sl unknown
- 2020-11-06 PT PT208083089T patent/PT3962601T/pt unknown
- 2020-11-06 HR HRP20230856TT patent/HRP20230856T1/hr unknown
- 2020-11-06 LT LTEPPCT/EP2020/081357T patent/LT3962601T/lt unknown
- 2020-11-06 WO PCT/EP2020/081357 patent/WO2021089824A1/en not_active Ceased
- 2020-11-06 JP JP2022525596A patent/JP7566021B2/ja active Active
- 2020-11-06 MA MA55821A patent/MA55821B1/fr unknown
- 2020-11-06 BR BR112022008037A patent/BR112022008037A2/pt unknown
- 2020-11-06 DK DK20808308.9T patent/DK3962601T3/da active
- 2020-11-06 FI FIEP20808308.9T patent/FI3962601T3/fi active
- 2020-11-06 HU HUE20808308A patent/HUE062369T2/hu unknown
- 2020-11-06 ES ES20808308T patent/ES2953926T3/es active Active
- 2020-11-06 PL PL20808308.9T patent/PL3962601T3/pl unknown
- 2020-11-06 CA CA3156513A patent/CA3156513A1/en active Pending
- 2020-11-06 CN CN202080078033.1A patent/CN114761083B/zh active Active
- 2020-11-06 AU AU2020379225A patent/AU2020379225B2/en active Active
-
2021
- 2021-06-16 US US17/349,255 patent/US11633390B2/en active Active
- 2021-07-06 US US17/368,351 patent/US11642336B2/en active Active
-
2022
- 2022-04-29 ZA ZA2022/04809A patent/ZA202204809B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20230856T1 (hr) | 2023-11-10 |
| US11246860B2 (en) | 2022-02-15 |
| US20210137908A1 (en) | 2021-05-13 |
| MD3962601T2 (ro) | 2023-10-31 |
| US11642336B2 (en) | 2023-05-09 |
| WO2021089824A1 (en) | 2021-05-14 |
| US11633390B2 (en) | 2023-04-25 |
| HUE062369T2 (hu) | 2023-10-28 |
| SI3962601T1 (sl) | 2023-10-30 |
| ES2953926T3 (es) | 2023-11-17 |
| FI3962601T3 (fi) | 2023-08-09 |
| CA3156513A1 (en) | 2021-05-14 |
| MA55821A (fr) | 2022-05-04 |
| BR112022008037A2 (pt) | 2022-07-12 |
| PT3962601T (pt) | 2023-08-28 |
| CN114761083B (zh) | 2024-02-13 |
| MA55821B1 (fr) | 2023-08-31 |
| EP3962601B1 (en) | 2023-05-31 |
| CN114761083A (zh) | 2022-07-15 |
| JP7566021B2 (ja) | 2024-10-11 |
| US20210330658A1 (en) | 2021-10-28 |
| IL292585A (en) | 2022-06-01 |
| JP2023501275A (ja) | 2023-01-18 |
| AU2020379225A1 (en) | 2022-05-26 |
| IL292585B2 (en) | 2023-08-01 |
| PL3962601T3 (pl) | 2023-10-09 |
| US20220062257A1 (en) | 2022-03-03 |
| ZA202204809B (en) | 2022-11-30 |
| IL292585B1 (en) | 2023-04-01 |
| AU2020379225B2 (en) | 2026-03-26 |
| EP3962601A1 (en) | 2022-03-09 |
| LT3962601T (lt) | 2023-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282487A (en) | Tyk2 inhibitors and uses thereof | |
| LT3962601T (lt) | 5-ht2a agonistai, skirti panaudoti depresijos gydymui | |
| IL282090A (en) | Tyk2 inhibitors and uses thereof | |
| EP3898592C0 (en) | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | |
| EP3898616C0 (en) | HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS | |
| DK4028010T3 (da) | Vs-6063 i kombination med ch5126766 til behandlingen af kræft | |
| DK3501542T3 (da) | Esketamin til behandling af depression | |
| DK3806898T3 (da) | Gremlin-1-antagonist til anvendelse i behandling af cancer | |
| DK3490582T3 (da) | Sammensætninger til anvendelse i behandling af myelofibrose | |
| LT3472153T (lt) | Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3285809T3 (da) | Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner. | |
| DK3429571T3 (da) | Kombinationer af lsd1-hæmmere til anvendelse til behandling af neoplastiske sygdomme | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| EP3494954A4 (en) | PHOTO-CURABLE COMPOSITION, DENTAL BASE AND REMOVABLE DENTAL PROSTHESIS | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3160234T3 (da) | Sammensætning til anvendelse til forebyggelse og behandling af oftalmisk-, hånd- eller fodbiofilmvækst | |
| EP3747920A4 (en) | COMPOSITION OF SEQUENCED COPOLYMER | |
| DK3570940T3 (da) | Pridopidin til anvendelse i behandling af fragilt x-syndrom | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| MX2019005322A (es) | Composiciones de recubrimiento y metodos de uso de las mismas. | |
| MX395032B (es) | Ciertos inhibidores de la proteína quinasa. | |
| EP3849570A4 (en) | Blood plasma-containing compositions | |
| DK4005570T3 (da) | Pridopidin til anvendelse behandling af retts syndroe | |
| DK3522904T3 (da) | Flydende sammensætning til anvendelse i behandlingen af gastroesophageal reflux |